Showing posts with label Patients. Show all posts
Showing posts with label Patients. Show all posts

Saturday, December 8, 2012

Pancreatic Cancer Discovery Offers New Hope For Patients

Editor's Choice
Main Category: Pancreatic Cancer
Also Included In: Cancer / Oncology
Article Date: 25 Oct 2012 - 12:00 PDT Current ratings for:
Pancreatic Cancer Discovery Offers New Hope For Patients
4 and a half starsnot yet rated
A set of mutated genes responsible for causing pancreatic cancer have been discovered by Australian researchers and revealed in a new study published in the journal Nature.

This is the first time a collaboration of the world's best experts has been carried out to determine the genetic factors that influence 50 different types of cancer.

According to the report, pancreatic cancer accounts for more deaths than any other major type of cancer. Survival rates have not improved over the last 40 years, acting as the fourth-leading cause of death from cancer. Common symptoms of pancreatic cancer include: NauseaVomiting Appetite LossPain in the upper part of the stomach (abdomen), which can spread to the backUnusual weight lossDiabetes mellitus or high levels of blood sugarDepression Trosseau sign (when blood clots pop up out of nowhere in the deep veins of a person's extremities, superficial veins anywhere on the body, or in the portal blood vesselsExperts noted that early pancreatic cancer sometimes does not come with any symptoms what-so-ever. According to previous research, pancreatic cancer patients' lives can be saved if they visit more experienced hospitals and facilities.

The international team of more than 100 researchers was led by Professor Sean Grimmon, from the Institute for Molecular Bioscience (IMB) at The University of Queensland, and Professor Andrew Biankin from The Kinghorn Cancer Centre at Garvan Institute of Medical Research / St. Vincent's Hospital in Sydney.

The experts sequenced the genomes from 100 pancreatic tumors and analyzed them in comparison with non-cancerous tissue to discover which genetic alterations may have caused the cancer.

Grimmon said:

"We found over 2,000 mutated genes in total, ranging from the KRAS gene, which was mutated in about 90 per cent of samples, to hundreds of gene mutations that were only present in 1 or 2 per cent of tumors. So while tumors may look very similar under the microscope, genetic analysis reveals as many variations in each tumor as there are patients. This demonstrates that so-called 'pancreatic cancer' is not one disease, but many, and suggests that people who seemingly have the same cancer might be to be treated quite differently."

Biankin commented that in the future, independent diagnoses and treatment plans for each patient will be the "norm". He said, "In this study, we found a set of genes, the axon guidance pathway, that is frequently damaged in pancreatic cancer patients and is associated with potentially poorer outcomes for those patients. It is a new marker of pancreatic cancer that can be used to direct prognoses and treatments."

Biankin continued: "'Personalized medicine', where the molecular profile of a patient is matched to the best treatment, is the way the world is moving for many diseases, not just cancer. The challenge now will be moving from population healthcare and a 'one drug fits all' model to personalized healthcare. First, we must take the time to develop the necessary genetic knowledge and implement health systems to translate that knowledge effectively."

The Professors noted that the Australian Pancreatic Cancer Genome Initiative, which involves over 20 hospitals and research facilities, of more than 200 nurses, surgeons, pathologists, and experts, played a large part in their study.

Professor Warwick Anderson, from the National Health and Medical Research Council of Australia, which funded the study with a $27.5 million grant, said: "NHMRC is proud to have been the major funding contributor to this research, and I am delighted that breakthroughs have been made in understanding the genetic basis of this disease. This positive outcome is evidence of NHMRC supporting the very best research and researchers, and the importance of our involvement in strong national and international collaborations. The ultimate goal of our funding is healthier citizens, both in Australia and overseas, and this research will certainly lead to a better understand of this issue."

Written by Christine Kearney
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our pancreatic cancer section for the latest news on this subject. "Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes" Andrew Biankin, Sean Grimmon, et.al.
Nature, October 2012, doi: 10.1038/nature11547 Please use one of the following formats to cite this article in your essay, paper or report:

MLA

n.p. "Pancreatic Cancer Discovery Offers New Hope For Patients." Medical News Today. MediLexicon, Intl., 25 Oct. 2012. Web.
12 Nov. 2012. APA

Please note: If no author information is provided, the source is cited instead.


posted by Kevin on 29 Oct 2012 at 7:47 am

Although this is definitely good news, the time something of real benefit comes out of it usually takes years, dare to say decades. My wife, 30-years old, she is suffering from this terrible disease. Just wish that more research is invested into it as much as any other form of cancer...Good luck with your wife Susanta

| post followup | alert a moderator |


posted by Susanta Kumar Das on 27 Oct 2012 at 6:44 am

We expect the outcome will delight the Patients. I am a badluck husband of a young 34 yeared pancreatic wife.
Presently she is undergoing treatment and 3rd stage of Chemotherapy is continue. Doctor diagonsis this position was not operable, only Chemothery (Paraplatin 450ml)may save her life.

Any new finding in this regards may comunicate to my mail ID. This may save her life.

Susanta Kumar Das

| post followup | alert a moderator |


'Pancreatic Cancer Discovery Offers New Hope For Patients'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Friday, December 7, 2012

Balancing Quality And Quantity Of Life For Pancreatic Cancer Patients

Main Category: Pancreatic Cancer
Article Date: 27 Aug 2012 - 0:00 PDT Current ratings for:
Balancing Quality And Quantity Of Life For Pancreatic Cancer Patients
not yet ratednot yet rated
Every year, nearly 45,000 Americans are diagnosed with pancreatic cancer. The odds against those stricken by the disease are truly dismal; pancreatic cancer almost always kills within two years after diagnosis, no matter how it is treated. Even aggressive intervention with chemotherapy, radiation or surgery rarely yields more than an extra month to a year of survival, depending on the stage of the disease.

This raises a tough question: should patients who know they are going to die soon spend a substantial amount of what little time they have left undergoing aggressive and difficult treatment - treatment likely to bring them only a brief period of additional life?

"It's about balancing quality and quantity of life, really," said Dr. Casey Boyd, a University of Texas Medical Branch at Galveston surgery resident and lead author of a paper analyzing the problem in Annals of Surgical Oncology. "For pancreatic cancer we know the quantity of life is short, so maximizing the quality of life is important - and the best way we can do that is to give patients concrete data that they can look at and use in their treatment decisions."

Boyd and her colleagues approached the issue by drawing on the National Cancer Institute's Surveillance, Epidemiology and End Results database, examining SEER records for 25,476 pancreatic cancer patients and focusing on two factors that directly affect patients' lives: hospital days and days spent in medical care. (Hospital days were days spent as hospital inpatients, while medical care days included days in the hospital as well as other days on which the patient visited a physician, underwent a diagnostic test, or received a treatment).

"This study is the first to bring together hospital and medical care days in pancreatic cancer patients with stage, treatment and survival, and it gives us a quantitative look at the whole experience of a patient with pancreatic cancer," Boyd said. "We hope that physicians can use the information in this paper to give patients what they need to make critical decisions."

For example, Boyd said, a doctor could draw on the paper to counsel a patient with metastatic pancreatic cancer - the most common and deadly type. "The physician could say, if you have chemotherapy you may live four to six weeks longer, but a lot of that time you're going to be in the hospital, or getting a test, or getting a needle poked in your arm for your chemotherapy," she said. "Some patients may say, I want that, I want the most life that you can give me."

Others, she noted, might make a different choice if given an accurate picture of the treatment experience.

"They might say, it's not really worth it to me - it's a few extra weeks, but they may be miserable weeks," Boyd said. "They may decide not to have any treatment and maybe just have hospice, or just spend time with their family."

The ability to help patients make such difficult decisions was the main goal of the study, according to Boyd.

"Really, this paper is about empowering the patient," she said. "We want to provide them with the information they need to make their own personalized treatment decisions."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our pancreatic cancer section for the latest news on this subject. Other authors of the Annals of Surgical Oncology article include medical student Daniel Branch, assistant professor Kristin Sheffield, biostatistician Yimei Han, associate professor Yong-Fang Kuo, Sealy Center on Aging director Dr. James Goodwin and associate professor Dr. Taylor Riall. Support for this research was provided by the NCI; the Office of Research, Development and Information, Centers for Medicare & Medicaid Services; Information Management Services Inc.; the SEER program; and the Cancer Prevention Research Institute of Texas.
University of Texas Medical Branch at Galveston Please use one of the following formats to cite this article in your essay, paper or report:

MLA

n.p. "Balancing Quality And Quantity Of Life For Pancreatic Cancer Patients." Medical News Today. MediLexicon, Intl., 27 Aug. 2012. Web.
12 Nov. 2012. APA

Please note: If no author information is provided, the source is cited instead.


'Balancing Quality And Quantity Of Life For Pancreatic Cancer Patients'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Monday, November 19, 2012

Whole Genome Sequencing Of Multiple Pancreatic Cancer Patients

Main Category: Pancreatic Cancer
Also Included In: Genetics
Article Date: 12 Oct 2012 - 0:00 PDT Current ratings for:
Whole Genome Sequencing Of Multiple Pancreatic Cancer Patients
5 stars5 stars
Whole genome sequencing - spelling out all 3 billion letters in the human genome - "is an obvious and powerful method for advancing our understanding of pancreatic cancer," according to a new study from TGen, Mayo Clinic and Scottsdale Healthcare.

The Translational Genomics Research Institute (TGen) demonstrated that the use of WGS "represents a compelling solution to obtaining detailed molecular information on tumor biopsies in order to provide guidance for therapeutic selection," concluded the study published by the journal PLOS ONE.

Examining three patients, the study spelled out the DNA of normal cells and compared that to the DNA of cells from biopsies of pancreatic adenocarcinoma (PAC), which makes up 95 percent of all pancreatic cancer tumors. Pancreatic cancer is the fourth leading cause of cancer death in the U.S.

Using next-generation sequencing, the study generated an average of 132 billion mappable bases, or data points, for each patient, resulting in the identification of 142 cellular genetic coding events, including mutations, insertions and deletions, and chromosomal copy number variants.

"This study is the first to report whole genome sequencing findings in paired tumor/normal samples collected from (three) separate PAC patients," said the report, which also was compiled with the collaboration of Mayo Clinic in Arizona, Arizona State University, and the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, which is a partnership between TGen and Scottsdale Healthcare.

In all three case studies, the report found multiple potential therapeutic targets, highlighting the need to study the full spectrum of the genome and re-emphasizing the need to develop multiple avenues of therapeutics to match the specific medical challenges of each patient.

"Cancer, and specifically here pancreatic cancer, is a highly complex disease that ultimately will require a variety of treatment methods to control, and ultimately to cure," said Dr. Daniel Von Hoff, TGen's Physician-In-Chief, and Chief Scientific Officer for the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

"This study shows that, as we continue to generate more information by sequencing the whole genomes of patients, we will continue to discover - with ever more confidence - the specific mechanisms that cause this cancer," said Dr. Von Hoff, one of the study's senior authors and one of the world's leading authorities on pancreatic cancer.

"We are very pleased to be working together with TGen in bringing hope and state of the art therapy to our patients at the Mayo Clinic Comprehensive Cancer Center," said Keith Stewart, M.B., Dean of Research at Mayo Clinic in Arizona, and the study's other senior author.

In the case of Patient 1, for example, genes previously associated with PAC were identified, including BRCA2, TP53, CDKN2A, MYC, SMAD4 and KRAS. But the study also made new discoveries. "Although BRCA2 mutations have been identified in PAC, the deletion we identify here in exon 10 of BRCA2 has not been previously reported," the study said.

Multiple therapeutics based on these findings were applied to Patient 1, who initially "showed a complete response,'' but developed drug resistance after six months.

"The BRCA2 deletion is likely the driving mutation in this patient as the loss of DNA repair functions permits the occurrence of mutations," the study said. "This finding and association provides evidence of the utility of performing whole genome analysis of patients in order to identify less common mutations that may be relevant for therapeutic selection."

WGS for Patient 2 and Patient 3 also uncovered multiple potential therapeutic targets through the identification of mutations and copy-number changes. In addition, RNA sequencing, or whole transcriptome analysis, of Patient 2 and Patient 3 revealed gene expression data that provided more information about likely affected biological processes.

Cellular pathway analysis of all sequencing data was also performed to identify processes that may be the most heavily impacted by cellular and gene expression alterations.

"As we continue to sequence patients, we will acquire a better understanding of the compendium of events that have a role in the disease, and strengthen our knowledge base for identifying and developing improved therapeutics," said Winnie Liang, Ph.D., Assistant Director of TGen's Collaborative Sequencing Center and one of the co-lead authors of the study.

"This study has demonstrated the feasibility of applying genome sequencing approaches toward eventual personalization and precision of therapy for patients with pancreatic cancer," said Dr. Mitesh Borad, hematologist/oncologist at Mayo Clinic in Arizona and co-author of the study. "Current studies are focusing on application of this approach in the clinical setting in a real time fashion."

Co-author Dr. Michael Demeure, Clinical Professor of TGen's Rare Cancer Unit and Scientific Director of the Endocrine and Rare Tumors Program at the Virginia G. Piper Cancer Center at Scottsdale Healthcare, said, "Whole genome sequencing provides us with the genetic blueprint and knowledge that is needed to crack the complex mysteries surrounding pancreatic cancer. For rare cancers where the data pool is relatively small, the potential for progress is particularly encouraging."

This groundbreaking study - Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing - was funded by: the National Foundation for Cancer Research, the Randy Pausch Scholarship Fund, and the Seena Magowitz Foundation. Additional support was provided by the Mayo Clinic Comprehensive Cancer Center, the U.S. Department of Health and Human Services, and supercomputing resources funded by the National Institutes of Health.

"This study represents a major step forward in the quest to find a cure for this cancer, which took the life of my mother, Seena. We are working harder than ever with TGen and others to continue this fight," said Roger Magowitz, President and co-founder of the Seena Magowitz Foundation.

"Whole genome sequencing is a new approach toward finding better treatments and to making these treatments available to cancer patients who need them now. We cannot emphasize enough the need for this kind of research," said Franklin C. Salisbury Jr., President of the NFCR.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our pancreatic cancer section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

n.p. "Whole Genome Sequencing Of Multiple Pancreatic Cancer Patients." Medical News Today. MediLexicon, Intl., 12 Oct. 2012. Web.
12 Nov. 2012. APA

Please note: If no author information is provided, the source is cited instead.


'Whole Genome Sequencing Of Multiple Pancreatic Cancer Patients'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Tuesday, November 13, 2012

Lives Could Be Saved By Referring Cancer Patients To More Experienced And Successful Hospitals For Surgery

Main Category: Pancreatic Cancer
Also Included In: Public Health;  Colorectal Cancer
Article Date: 21 Oct 2012 - 0:00 PDT Current ratings for:
Lives Could Be Saved By Referring Cancer Patients To More Experienced And Successful Hospitals For Surgery
4 starsnot yet rated
Researchers at Rice University report that referring cancer patients to hospitals with better track records for surgery could save lives and not raise the cost to patients. The study was reported online in the journal Forum for Health Economics and Policy.

The researchers reviewed data on two cancer operations that are at "opposite ends of the spectrum" - colon and pancreatic resections, said paper author Vivian Ho, Rice University's Baker Institute Chair in Health Economics and a professor of economics. Pancreatic resection is performed much less often than colon resection, but it's a very complicated operation that can take 5 to 8 hours and has a much higher mortality rate. Colon resection is more straightforward, is performed much more often and has a much lower mortality rate.

"If all patients needing surgery for colon cancer were referred to hospitals that have consistently achieved mortality rates in the bottom half of all hospitals performing this operation, then the average mortality rate could fall from a rate of 3.8 percent to 2.4 percent," Ho said. "And if all patients who require surgical resection for pancreatic cancer were referred to hospitals performing 11 or more of these operations per year, mortality rates could fall by half, from a rate of 6 percent to 3 percent."

The analysis was based primarily on hospital records for all patients who received surgery for colon cancer or pancreatic cancer in California, Florida, New Jersey or New York between 2001 and 2005. This data was combined with hospital information from the American Hospital Association, the Medicare program and MarketScan Research Data. The researchers used this data to determine the association between the number of surgical operations performed each year and patient mortality rates for each cancer type. Regression analysis was used to adjust for multiple differences in patient characteristics that are important determinants of patient mortality.

The investigators then used their regression analyses to simulate how mortality rates might change if, for instance, patients at poorly performing hospitals were referred to the closest hospital that had achieved mortality rates (adjusted for differences in patient characteristics) in the lower half of the distribution relative to all other hospitals in their state between 2001 and 2005.

For colon cancer patients, higher-volume hospitals did not achieve lower mortality rates than hospitals that performed fewer colon resections per year. However, many hospitals performed consistently better than others in terms of lower patient mortality during the study period, Ho said.

"We were concerned that the centralization of cancer care that would result from referring patients to a smaller set of higher-volume hospitals could give these hospitals additional market power to raise prices," Ho said. "We also wondered whether higher-volume hospitals might have a different cost structure that would raise or lower costs per patient. We found no statistical evidence that hospitals that performed more of these cancer operations were able to charge higher prices to patients for these services. We found that costs per patient were indeed higher for hospitals performing more pancreatic cancer surgery. However, these higher costs were not passed on to patients as higher prices for patient care."

Ho recommended that mechanisms be constructed to refer cancer patients to those hospitals where they are likely to achieve better outcomes. "Some states already post information on their health department's website on the number of pancreatic cancer surgeries performed by each hospital per year, or inpatient mortality rates adjusted for patient characteristics. Private not-for-profit organizations such as the American Cancer Society and the American College of Surgeons could partner with public national and state organizations to replicate the information in our study and make it available to referring physicians and their patients."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our pancreatic cancer section for the latest news on this subject.
The study was supported by a grant from the National Cancer Institute at the National Institutes of Health.

The study, “Can Centralization of Cancer Surgery Improve Social Welfare?”: http://www.degruyter.com/view/j/fhep.2012.15.issue-3/issue-files/fhep.2012.15.issue-3.xml

Rice University

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

n.p. "Lives Could Be Saved By Referring Cancer Patients To More Experienced And Successful Hospitals For Surgery." Medical News Today. MediLexicon, Intl., 21 Oct. 2012. Web.
12 Nov. 2012. APA

Please note: If no author information is provided, the source is cited instead.


'Lives Could Be Saved By Referring Cancer Patients To More Experienced And Successful Hospitals For Surgery'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here